Mobile

A study to find out if a vaccine designed to protect against a disease (group B meningococcal meningitis) is safe and protects children aged from 24 months to less than 10 years

Update Il y a 4 ans
Reference: EUCTR2014-000933-21

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

•To describe the immune response as measured by hSBA performed with 4 primary MnB test strains, 2 expressing an LP2086 subfamily A protein and 2 expressing an LP2086 subfamily B protein, measured 1 month after the third vaccination with bivalent rLP2086, in healthy subjects aged ≥24 months to <4 years at study entry. •To describe the immune response as measured by hSBA performed with 4 primary MnB test strains, 2 expressing an LP2086 subfamily A protein and 2 expressing an LP2086 subfamily B protein, measured 1 month after the third vaccination with bivalent rLP2086, in healthy subjects aged ≥4 years to <10 years at study entry.

Inclusion criteria

  • Invasive meningococcal disease (IMD) caused by Neisseria meningitidis
  • serogroup B

Links